Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4209

Sort by

Sort Order Select

Journal Articles

AML onco-niche: villain or ally?

Marta Derecka

Blood (2021) 138 (7): 504–506.

https://doi.org/10.1182/blood.2021012299

Published: 2021

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells

Kimihito C. Kawabata, Hongliang Zong, Cem Meydan, Sarah Wyman, Bas J. Wouters, Mayumi Sugita, Srinjoy Goswami, Michael Albert, Winnie Yip, Gail J. Roboz, Zhengming Chen, Ruud Delwel, Martin Carroll, Christopher E. Mason, Ari Melnick, Monica L. Guzman

Blood (2021) 137 (6): 812–825.

https://doi.org/10.1182/blood.2019001745

Published: 2021

Includes: Supplemental data

Journal Articles

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Blood (2020) 135 (24): 2137–2145.

https://doi.org/10.1182/blood.2020004856

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat acute myeloid leukemia in the era of new drugs

Courtney D. DiNardo, Andrew H. Wei

Blood (2020) 135 (2): 85–96.

https://doi.org/10.1182/blood.2019001239

Published: 2020

Includes: Supplemental data

Journal Articles

Risk Factors for Increased Length of Stay (LOS) in Patients with Hematological Malignancies Electively Admitted for Chemotherapy

Christopher E. Wee, MD, Jilan Kubusek, PharmD, Irbaz Riaz, MDMMSc, Robert Wolf, PharmD, RPh, Julian R Molina, MD PhD, Naseema Gangat, MBBS

Blood (2019) 134 (Supplement_1): 2138.

https://doi.org/10.1182/blood-2019-127367

Published: 2019

Journal Articles

Mechanisms of Tolerance Induction through T Regulatory Cells during Chemotherapy-Mediated Immunogenic Cell Death in Acute Myeloid Leukemia

Darina Ocadlikova, PhD, Serenella Casella, Ines Pintao, Elena Adinolfi, Sabina Sangaletti, PhD, Elena De Marchi, Anna Pegoraro, Elisa Orioli, Mario Paolo Colombo, Francesco Di Virgilio, Michele Cavo, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 2332.

https://doi.org/10.1182/blood-2019-126478

Published: 2019

Journal Articles

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Noam E. Kopmar, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Roland B. Walter, MDPhDMS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 2214.

https://doi.org/10.1182/blood-2019-123315

Published: 2019

Journal Articles

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Kwanza Price, MPH, Zhun Cao, PhD, Craig Lipkin, Scott Robinson, Deborah Ann Profant, PhD

Blood (2019) 134 (Supplement_1): 2213.

https://doi.org/10.1182/blood-2019-127075

Published: 2019

Journal Articles

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Fernanda Marconi Roversi, Maura Lima Pereira Bueno, undergraduate, Cristiane Okuda Torello, PhD, Fernanda I Della Via, MSc, Renata Giardini Rosa, PhD, Juares Ednaldo Romero Bianco, PhD, Adriana Silva Santos Duarte, PhD, Eduardo M Rego, MD PhD, Alessio Molinari, Maurizio Botta, Sara T Olalla Saad, PhD

Blood (2019) 134 (Supplement_1): 4650.

https://doi.org/10.1182/blood-2019-128959

Published: 2019

Journal Articles

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Bernice Oh, MBBS, MRCP, Shawn Lee, MD, Zelia Seeto, Germaine Liew, Bsc, Edwynn Chiew, MBBS, Zhi Wei Chen, Bsc, Yiong Huak Chan, PhD, Jing Jia Eng, Bsc, Koon Mian Foo, Bsc, Ching Mei Joyce Lam, MD, Ah Moy Tan, MD, Allen Eng Juh Yeoh, MD

Blood (2019) 134 (Supplement_1): 1307.

https://doi.org/10.1182/blood-2019-122098

Published: 2019

Journal Articles

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Selina M. Luger, MD FRCPC, Zhuoxin Sun, PhD, Sanam Loghavi, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MB, BS, Martin S. Tallman, MD, Keith W. Pratz, MD, Mark Litzow, MD

Blood (2019) 134 (Supplement_1): 1309.

https://doi.org/10.1182/blood-2019-128377

Published: 2019

Journal Articles

Identifying the Leukemia Stem Cell Niche Mediating Drug Resistance in Flt3-ITD Acute Myeloid Leukemia

Nick R Anderson, BS, Hui Li, BS, Mason W Harris, Shaowei Qiu, MD, Andrew J Paterson, PhD, Ravi Bhatia, MD

Blood (2019) 134 (Supplement_1): 909.

https://doi.org/10.1182/blood-2019-124379

Published: 2019

Journal Articles

Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial

Blood (2019) 134 (Supplement_1): 826.

https://doi.org/10.1182/blood-2019-123613

Published: 2019

Journal Articles

CD162 Is a Key E-Selectin Receptor Promoting Acute Myeloid Leukemia Chemo-Resistance in the Bone Marrow Niche

Johanna D Erbani, Joshua Tay, PhD, Valerie Barbier, Masters, Jean-Pierre Levesque, PhD, John L. Magnani, PhD, Ingrid G Winkler, PhD

Blood (2019) 134 (Supplement_1): 907.

https://doi.org/10.1182/blood-2019-132233

Published: 2019

Journal Articles

Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Blood (2019) 134 (Supplement_1): 735.

https://doi.org/10.1182/blood-2019-122779

Published: 2019

Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 823.

https://doi.org/10.1182/blood-2019-125136

Published: 2019

Journal Articles

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens

Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 738.

https://doi.org/10.1182/blood-2019-128909

Published: 2019

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

NARROW

AML onco-niche: villain or ally?

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

How I treat acute myeloid leukemia in the era of new drugs

Risk Factors for Increased Length of Stay (LOS) in Patients with Hematological Malignancies Electively Admitted for Chemotherapy

Mechanisms of Tolerance Induction through T Regulatory Cells during Chemotherapy-Mediated Immunogenic Cell Death in Acute Myeloid Leukemia

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Identifying the Leukemia Stem Cell Niche Mediating Drug Resistance in Flt3-ITD Acute Myeloid Leukemia

CD162 Is a Key E-Selectin Receptor Promoting Acute Myeloid Leukemia Chemo-Resistance in the Bone Marrow Niche

Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only